Cas9 immunity creates challenges for CRISPR gene editing therapies

by Julie M. Crudele, Jeffrey S. Chamberlain
Published 2018-08-01

Microutrophin expression in dystrophic mice displays myofiber type differences in therapeutic effects.

by Glen B Banks, Jeffrey S Chamberlain, Guy L Odom
Published 2020-11-01

Immunity and AAV-mediated gene therapy for muscular dystrophies in large animal models and human trials

by Zejing eWang, Stephen J Tapscott, Stephen J Tapscott, Jeffrey S Chamberlain, Jeffrey S Chamberlain, Rainer eStorb, Rainer eStorb
Published 2011-09-01

Immune responses to rAAV6: The influence of canine parvovirus vaccination and neonatal administration of viral vector

by Andrea L H Arnett, Andrea L H Arnett, Dilip eGarikipati, Zejing eWang, Stephen J Tapscott, Jeffrey S Chamberlain, Jeffrey S Chamberlain
Published 2011-11-01

Multi-parametric MRI at 14T for muscular dystrophy mice treated with AAV vector-mediated gene therapy.

by Joshua Park, Jacqueline Wicki, Sue E Knoblaugh, Jeffrey S Chamberlain, Donghoon Lee
Published 2015-01-01

The polyproline site in hinge 2 influences the functional capacity of truncated dystrophins.

by Glen B Banks, Luke M Judge, James M Allen, Jeffrey S Chamberlain
Published 2010-05-01

Engraftment potential of dermal fibroblasts following in vivo myogenic conversion in immunocompetent dystrophic skeletal muscle

by Lindsey A Muir, Quynh G Nguyen, Stephen D Hauschka, Jeffrey S Chamberlain
Published 2014-01-01

L-type Ca2+ channel function is linked to dystrophin expression in mammalian muscle.

by Oliver Friedrich, Frederic von Wegner, Jeffrey S Chamberlain, Rainer H A Fink, Petra Rohrbach
Published 2008-01-01

Non-invasive tracking of disease progression in young dystrophic muscles using multi-parametric MRI at 14T.

by Joshua S Park, Ravneet Vohra, Thomas Klussmann, Niclas E Bengtsson, Jeffrey S Chamberlain, Donghoon Lee
Published 2018-01-01

Muscle structure influences utrophin expression in mdx mice.

by Glen B Banks, Ariana C Combs, Guy L Odom, Robert J Bloch, Jeffrey S Chamberlain
Published 2014-06-01

Functional deficits in nNOSmu-deficient skeletal muscle: myopathy in nNOS knockout mice.

by Justin M Percival, Kendra N E Anderson, Paul Gregorevic, Jeffrey S Chamberlain, Stanley C Froehner
Published 2008-01-01

Expressing a Z-disk nebulin fragment in nebulin-deficient mouse muscle: effects on muscle structure and function

by Frank Li, Justin Kolb, Julie Crudele, Paola Tonino, Zaynab Hourani, John E. Smith, Jeffrey S. Chamberlain, Henk Granzier
Published 2020-01-01

Correction to: Expressing a Z-disk nebulin fragment innebulin-deficient mouse muscle: effects on muscle structure and function

by Frank Li, Justin Kolb, Julie Crudele, Paola Tonino, Zaynab Hourani, John E. Smith, Jeffrey S. Chamberlain, Henk Granzier
Published 2020-04-01

Inhibitory control over Ca(2+) sparks via mechanosensitive channels is disrupted in dystrophin deficient muscle but restored by mini-dystrophin expression.

by Martin D H Teichmann, Frederic V Wegner, Rainer H A Fink, Jeffrey S Chamberlain, Bradley S Launikonis, Boris Martinac, Oliver Friedrich
Published 2008-01-01

Adeno-associated viral vectors do not efficiently target muscle satellite cells

by Andrea LH Arnett, Patryk Konieczny, Julian N Ramos, John Hall, Guy Odom, Zipora Yablonka-Reuveni, Joel R Chamberlain, Jeffrey S Chamberlain
Published 2014-01-01

Muscle fiber type-predominant promoter activity in lentiviral-mediated transgenic mouse.

by Tomohiro Suga, En Kimura, Yuka Morioka, Masahito Ikawa, Sheng Li, Katsuhisa Uchino, Yuji Uchida, Satoshi Yamashita, Yasushi Maeda, Jeffrey S Chamberlain, Makoto Uchino
Published 2011-03-01

Micro-utrophin Improves Cardiac and Skeletal Muscle Function of Severely Affected D2/mdx Mice

by Tahnee L. Kennedy, Simon Guiraud, Ben Edwards, Sarah Squire, Lee Moir, Arran Babbs, Guy Odom, Diane Golebiowski, Joel Schneider, Jeffrey S. Chamberlain, Kay E. Davies
Published 2018-12-01

Micro-dystrophin gene therapy prevents heart failure in an improved Duchenne muscular dystrophy cardiomyopathy mouse model

by Zachary M. Howard, Lisa E. Dorn, Jeovanna Lowe, Megan D. Gertzen, Pierce Ciccone, Neha Rastogi, Guy L. Odom, Federica Accornero, Jeffrey S. Chamberlain, Jill A. Rafael-Fortney
Published 2021-04-01

Correction: Corrigendum: Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy

by Niclas E. Bengtsson, John K. Hall, Guy L. Odom, Michael P. Phelps, Colin R. Andrus, R. David Hawkins, Stephen D. Hauschka, Joel R. Chamberlain, Jeffrey S. Chamberlain
Published 2017-06-01

Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy

by Niclas E. Bengtsson, John K. Hall, Guy L. Odom, Michael P. Phelps, Colin R. Andrus, R. David Hawkins, Stephen D. Hauschka, Joel R. Chamberlain, Jeffrey S. Chamberlain
Published 2017-02-01